Inactive Instrument
Erin Resources Ltd Stock Australian S.E.
Stocks
AU000000ERI2
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Australian S.E.
|
||
| - AUD | - |
|
| 08-31 | Argent BioPharma Limited Reports Earnings Results for the Full Year Ended June 30, 2026 | CI |
| 08-30 | Argent BioPharma Limited Auditor Raises 'Going Concern' Doubt | CI |
| Market Cap | 3.5M 2.43M 2.14M 2.03M 1.83M 3.45M 233M 24.28M 9.35M 119M 9.13M 8.94M 382M | P/E 2025 |
-0.26x | P/E 2026 | -0.4x |
|---|---|---|---|---|---|
| Enterprise Value | 12.95M 9M 7.93M 7.51M 6.78M 12.78M 863M 89.86M 34.58M 441M 33.8M 33.07M 1.41B | EV / Sales 2025 |
72.6x | EV / Sales 2026 | 83.4x |
| Free-Float |
38.56% | Yield 2025 * |
-
| Yield 2026 | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Roby Zomer
CEO | Chief Executive Officer | 46 | 2017-05-11 |
Yifat Steuer
COO | Chief Operating Officer | 55 | 2022-10-03 |
Nadya Lisovoder
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Roby Zomer
CHM | Chairman | 46 | 2026-05-05 |
Daniel Robinson
BRD | Director/Board Member | - | 2023-11-30 |
Andrew Chapman
BRD | Director/Board Member | - | 2026-05-05 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.16% | -0.36% | +49.37% | +94.17% | 71.53B | |
| -0.19% | +1.32% | +37.20% | +83.85% | 60.12B | |
| -1.51% | +2.39% | +9.10% | +35.15% | 48.85B | |
| -0.05% | +0.37% | +41.54% | +36.65% | 44.28B | |
| +0.38% | +7.61% | +339.53% | +641.55% | 43.83B | |
| +0.18% | +0.26% | +7.41% | +103.45% | 41.53B | |
| -0.67% | +0.17% | +7.60% | +46.37% | 30.13B | |
| +4.77% | +6.16% | +36.77% | +22.78% | 27.98B | |
| -1.29% | -3.55% | -20.74% | +352.04% | 25.25B | |
| Average | +0.64% | +1.18% | +56.42% | +157.33% | 43.72B | |
| Weighted average by Cap. | +0.80% | +1.37% | +60.93% | +148.55% |
| 2025 | 2026 | |
|---|---|---|
| Net sales | 181K 126K 111K 105K 94.58K 178K 12.04M 1.25M 482K 6.15M 472K 461K 19.73M | 161K 112K 98.71K 93.52K 84.43K 159K 10.75M 1.12M 431K 5.49M 421K 412K 17.62M |
| Net income | -17.84M -12.41M -10.93M -10.35M -9.35M -17.62M -1.19B -124M -47.67M -608M -46.6M -45.58M -1.95B | -7.71M -5.36M -4.72M -4.47M -4.04M -7.61M -514M -53.52M -20.6M -263M -20.13M -19.69M -843M |
| Net Debt | 7.26M 5.05M 4.45M 4.21M 3.8M 7.17M 484M 50.42M 19.4M 248M 18.97M 18.55M 794M | 9.45M 6.57M 5.79M 5.48M 4.95M 9.33M 630M 65.58M 25.24M 322M 24.67M 24.13M 1.03B |
Employees
-
Select your edition
All financial news and data tailored to specific country editions
